Novartis India: Disclosure of the receipt of In-principle approval from the Stock Exchange i.e. BSE Limited in relation to…

What happened

Novartis India (NOVARTIND) filed a disclosure with the exchanges on 1 November 2026 at 02:24 PM titled "Disclosure of the receipt of In-principle approval from the Stock Exchange i.e. BSE Limited in relation to the draft Letter of Offer".

Company snapshot

Novartis India is a small-cap company, with a market value of about ₹4,179 crore.

The stock last traded at ₹1,692.4, against a 52-week range of ₹672.3–₹2,588.8 (34.6% below the high).

Before this filing the shares had moved −11.8% over the month and +3.5% over three months. Average daily turnover over the last 20 sessions was about ₹8.46 crore.

Promoters held 70.68% at the end of Q2 FY27. Foreign institutions owned 0.15% and domestic institutions 1.39%.

What history shows

BCEIE's records show 1 previous approval filing from the company since May 2026.

Market-wide, 1,547 approval filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 47% rising.

Past reactions describe what happened before; they are not a forecast.

In the news

Recent coverage elsewhere (links open the original publisher):

• Novartis CEO unfazed by high-profile clinical failures, maintains long-term revenue goal — Fierce Pharma, 27 Oct 2026
• Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail — Fierce Biotech, 27 Oct 2026
• Novartis results: buying lower or selling higher, when the big moves come from elsewhere — Saxo, 23 Oct 2026
• Novartis presents positive results from two phase 3 trials for relapsing MS — PMLiVE, 28 Oct 2026
• Novartis raises profit outlook after strong Q3 sales growth; shares rise — Investing.com, 27 Oct 2026

Source

• Exchange filing (PDF)